A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Novel ectopic expression of zona pellucida 3 glycoprotein in lung cancer promotes tumor growth
Tekijät: Pulawska-Moon, Kamila; Ponikwicka-Tyszko, Donata; Lebiedzinska, Weronika; Pilaszewicz-Puza, Agata; Bernaczyk, Piotr; Koda, Mariusz; Lupu, Oana; Milewska, Gabriela; Huang, Chen-Che Jeff; Zheng, Huifei; Schiele, Phillip; Na, Il-Kang; Frentsch, Marco; Li, Xiangdong; Toppari, Jorma; Wolczynski, Slawomir; Coelingh Bennink, Herjan J. T.; Huhtaniemi, Ilpo; Rahman, Nafis A.
Kustantaja: John Wiley & Sons
Julkaisuvuosi: 2024
Journal: International Journal of Cancer
Tietokannassa oleva lehden nimi: International journal of cancer
Lehden akronyymi: Int J Cancer
Vuosikerta: 155
Numero: 10
Aloitussivu: 1846
Lopetussivu: 1857
ISSN: 0020-7136
eISSN: 1097-0215
DOI: https://doi.org/10.1002/ijc.35098
Verkko-osoite: https://onlinelibrary.wiley.com/doi/10.1002/ijc.35098
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/457303122
Zona pellucida 3 (ZP3) expression is classically found in the ZP-layer of the oocytes, lately shown in ovarian and prostate cancer. A successful ZP3 ovarian cancer immunotherapy in transgenic mice suggested its use as an attractive therapeutic target. The biological role of ZP3 in cancer growth and progression is still unknown. We found that ~88% of the analyzed adenocarcinoma, squamous and small cell lung carcinomas to express ZP3. Knockout of ZP3 in a ZP3-expressing lung adenocarcinoma cell line, significantly decreased cell viability, proliferation, and migration rates in vitro. Zona pellucida 3 knock out (ZP3-KO) cell tumors inoculated in vivo in immunodeficient non-obese diabetic, severe combined immunodeficient mice showed significant inhibition of tumor growth and mitigation of the malignant phenotype. RNA sequencing revealed the deregulation of cell migration/adhesion signaling pathways in ZP3-KO cells. This novel functional relevance of ZP3 in lung cancer emphasized the suitability of ZP3 as a target in cancer immunotherapy and as a potential cancer biomarker.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
This study was partially supported by grants from the Ella and Georg Ehrnrooth Foundation (K.P.-M.), Pantharhei Bioscience/Oncology (N.A.R.), Medical University of Bialystok SUB/1/DN/20/005/1104 (S.W.), Magnus Ehrnrooth Foundation (N.A.R.), and Turku University Hospital (J.T.).
